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Aggressive periodontitisAbstract Aim: To study the effect of nonsurgical periodontal therapy on the expression frequen-
cies of human beta-defensin (HBD)-1, -2, and -3 in the gingival crevicular ﬂuid (GCF) of patients
affected by localized aggressive periodontitis.
Materials and methods: Twenty patients affected by localized aggressive periodontitis (age range,
20–35 years) and 20 healthy subjects (age range, 21–37 years) were examined with clinical periodon-
tal parameters and radiographic examination with the long-cone parallel technique. All periodon-
titis patients underwent nonsurgical periodontal therapy combined with doxycycline treatment and
a maintenance program (including brushing with regular toothpaste). GCF samples were collected
from patients and healthy control subjects at baseline as well as 3 months after periodontal therapy
for the patient group.
Results: In the patient group, the expression frequencies of HBD-1, -2, and -3 mRNA at baseline
were 30%, 85%, and 35%, respectively, which changed after periodontal therapy to 80%, 45%, and
85%, respectively (all P< 0.001). In the healthy control subjects, the expression frequencies were
95%, 40%, and 95% for HBD-1, -2, and -3, respectively, which were different from those of dis-
eased patients at baseline (all P< 0.001).
Conclusions: The appropriate expression of HBD peptides in health and disease may contribute
to the maintenance of periodontal homeostasis, possibly through its antimicrobial effects and the
promotion of adaptive immune responses.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Three subfamilies of human defensins have been identiﬁed: a-
defensins, b-defensins, and h-defensins (Karl et al., 2010). The
a-defensins are also known as human neutrophil peptides and
are found in neutrophils as azurophilic granules; these defen-
sins attack microorganisms that have been phagocytosed by
neutrophils and macrophages (Ganz and Lehrer, 1995). Six
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and Bevins, 1993; Porter et al., 1997) and four types of
b-defensins have been identiﬁed (Ganz, 1987; Harder et al.,
2001; Lu et al., 2004; Mathews et al., 1999). Defensins chemo-
attract monocytes and macrophages, as well as T-lymphocytes,
mast cells, and immature dendritic cells, and trigger the pro-
duction of proinﬂammatory cytokines (Porter et al., 1997).
Human b-defensins (HBDs) suppress the production of proin-
ﬂammatory cytokines in response to speciﬁc microbial anti-
gens, activate and degranulate mast cells, regulate the
complement system, inhibit glucocorticoid production, and en-
hance antigen-speciﬁc immune responses (Porter et al., 1997).
The gingival epithelium is considered to be the ﬁrst line of
defense against microbes due to its barrier function that phys-
ically prevents microbial invasion and its antimicrobial proper-
ties that counteract the action of putative pathogens (Garcia
et al., 2001a,b; Bensch et al., 1995). Periodontal diseases are
caused by a disturbance in the bacteria–host equilibrium in
the buccal cavity that results in the destruction of tooth-sup-
porting tissues (Diamond et al., 2001; Darveau et al., 2000).
HBDs have been detected in gingival epithelia (Garcia et al.,
2001a,b), salivary glands and saliva (Bensch et al., 1995),
and gingival crevicular ﬂuid (GCF) (Garcia et al., 2001a,b).
HBD-1 and HBD-2 are active against gram-negative bacteria
and yeast, with restricted activity against gram-positive bacte-
ria (Quayle et al., 1998). Most studies have found HBD-1 to be
upregulated in various epithelia, whereas HBD-2 is signiﬁ-
cantly induced in inﬂamed tissues (Darveau et al., 2000; Page
et al., 1997). However, other studies have shown an upregula-
tion of HBD-1 in response to inﬂammation (Aas et al., 2005),
and Zhao et al. (1996) reported decreased expression of HBD-
2 in inﬂamed tissues, a reﬂection of the complexity of inﬂam-
matory diseases. HBD-3 is widely expressed in human tissues
(Ganz and Lehrer, 1995). However, there is little information
on its expression pattern in gingival tissues or crevicular ﬂuid
(Lu et al., 2005). HBD-3 has potent antimicrobial activities
against both gram-positive and gram-negative bacteria when
compared with HBD-1 and HBD-2, even at low concentra-
tions (Zhao et al., 1996).
Microbial signals, developmental signals, cytokines, and, in
some cases, neuroendocrine signals regulate defensin synthesis
and release (Tomas Ganz, 2003). Interferon (IFN)-c and inter-
leukins (IL)-1b, IL-6, and IL-10 have varied effects on the
expression of human defensin genes (Tomas Ganz, 2003).
Whereas the expression of HBD-1 is largely unaffected by cyto-
kines, and HBD-2 expression is only induced by IL-1b, the
expression of HBD-3 is regulated by IFN-c, IL-1b, and IL-10.
Stimulations of tumor necrosis factor (TNF)-a and IFN-c in-
crease HBD-3 gene expression, whereas IL-13 and IL-4 inhibit
its expression (Pingel et al., 2008). The various expression levels
of theHBDsmay lead to different defensin proﬁles andmay cor-
relate with susceptibility to bacterial infections, Crohn’s disease,
periodontal disease, and cystic ﬁbrosis (Karl et al., 2010).
The initiation and progression of periodontal disease is re-
lated to the colonization of the gingival crevice by speciﬁc
microorganisms, and their subsequent subgingival prolifera-
tion. The organisms involved include Aggregatibacter (Actino-
bacillus) actinomycetemcomitans and members of the so-called
‘red complex’ of periodontopathogenic bacteria (Porphyro-
monas gingivalis, Tannerella forsythia, and Treponema dentico-
la), most of which are regularly isolated from aggressive
periodontitis (Marta Gajardo et al., 2005). An effective hostresponse to this bacterial challenge is primarily mediated by
neutrophils and is characterized by an inﬂux of neutrophils
into the gingival crevice, followed by the expression and release
of a- and b-defensins (Puklo et al., 2008).
The aim of the present study was to investigate changes in
the expression patterns of HBD-1, -2, and -3 in the GCF of
patients affected by localized aggressive periodontitis after
nonsurgical periodontal therapy.2. Subjects and methods
2.1. Subjects
Twenty patients (age range, 20–35 years) affected by localized
aggressive periodontitis were selected from the outpatient
clinic of the Oral Medicine and Periodontology Department,
Faculty of Oral and Dental Medicine, Minia University,
Egypt. Patient selection was based on the classiﬁcation of peri-
odontal diseases by the International Workshop for Classiﬁca-
tion of Periodontal Diseases and Conditions of the American
Academy of Periodontology in 1999 (Armitage, 1999). The cri-
teria for inclusion in the study were: radiographic bone loss of
more than 50% in at least two different teeth; patient aged less
than 35 years at the onset of the disease; no history of antibi-
otic therapy during the preceding 6 months; patients should be
systemically free; and no history of receiving any prior immu-
nosuppressive therapy. Twenty healthy subjects (age range,
21–37 years) were included in the study as a control group.
The control subjects did not show any site with a probing
depth greater than 3 mm. They did not show attachment loss
in any quadrant or radiographic evidence of bone loss, and
exhibited bleeding on probing in less than 20% of sites.
Healthy subjects were selected from the orthodontic and surgi-
cal departments.
Written and oral informed consents were obtained from all
subjects for inclusion in the study. The study complied with the
rules set by the International Conference on Harmonisation of
Good Clinical Practice Guidelines and the Declaration of Hel-
sinki. The study protocol was approved by the Ethics Commit-
tee of the Faculty of Oral and Dental Medicine, Minia
University. This study was funded by the author’s speciﬁc
funding and the facilities were supplied by the Faculty of Oral
and Dental Medicine, Minia University. There was no major
ﬁnancial support for this work that could have inﬂuenced its
outcomes.
For each patient, the following parameters were recorded at
baseline and 3 months after periodontal therapy: plaque index
(PLI), gingival index (GI), pocket depth (PD; measured with a
graduated periodontal probe), and clinical loss of attachment
(CLA). Ramfjord teeth or their substitutes were the target
teeth for the collection of these parameters. These parameters
were also recorded for the healthy control subjects at baseline.
Periapical radiographs with the long-cone parallel technique
were taken for each patient to detect levels of bone loss.2.2. Collection of samples
For every patient and control subject, GCF samples were
collected at baseline and 3 months after periodontal therapy.
The samples were pooled from four periodontal sites with
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rants). The sampling area was isolated with cotton rolls and
carefully cleaned supragingivally with sterile cotton pellets. A
sterile absorbent paper point was inserted into the gingival cre-
vice or pocket until resistance was felt. The paper point was
held in place for 30 s and then was transferred to a vial con-
taining 100 lL of distilled water and vigorously mixed. The pa-
per points were removed, and the samples were centrifuged
and washed twice with distilled water. The resultant pellets
were resuspended in 0.4 mL of distilled water. The samples
were coded and stored at 70 C until use for reverse tran-
scription polymerase chain reaction (RT-PCR) analysis.
2.3. Periodontal therapy
Every patient was subjected to full-mouth supra- and subgin-
gival scaling and root planning using an ultrasonic scaler
and periodontal curettes. Debridement was completed in three
sessions over a 2-week period. The patients were instructed to
use chlorhexidine mouthwash (Hexitol) and an antibiotic reg-
imen in the form of 100 mg doxycycline (Vibramycin capsules)
two times per day for 10 days. The aim of this treatment was
not only to reduce bacterial infection, but also to reduce
inﬂammation and to help to block collagenase activity.
All patients were instructed to follow a maintenance pro-
gram by using a soft toothbrush (Formula system) three times
daily with regular toothpaste (Signal 2) and interdental tooth
picks (Jordan), with regular recall visits every 3 weeks for a
2-month period.
2.4. RT-PCR assay
Samples were processed blindly for the detection of mRNA
transcripts of HBD-1, -2, and -3 by RT-PCR. The total cellular
RNA was isolated from each sample pellet with a monophasic
solution of phenol and guanidine thiocyanate (Trizol), as rec-
ommended by the supplier (Invitrogen, Paisley, United King-
dom). To generate cDNA, 2–4 lg of total cellular RNA was
transcribed at 42 C for 50 min in a 20-ll reaction volume con-
taining 50 mM Tris (pH 8.3), 75 mM KCl, 3 mM MgCl2,
3 mM dithiothreitol, 10 mM deoxynucleoside triphosphate
mix, 0.5 lg of oligo (dT), and 100 U of Moloney murine leuke-
mia virus reverse transcriptase. PCR ampliﬁcation was con-
ducted in 50-ll of reaction volume [10 mM Tris (pH 9.0),
50 mM KCl, 1.5 mM MgCl2], 200 lM concentration of each
of the four deoxynucleoside triphosphates, and 20 pmol of spe-
ciﬁc 50 and 30 primers (Invitrogen) (Table 1), plus 1 U of Taq
DNA polymerase.
The ampliﬁcation temperature proﬁle consisted of denatur-
ation at 94 C for 90 s, annealing at 58 C for 90 s, and exten-
sion at 72 C for 90 s for 40 cycles. PCR products wereTable 1 Primer sequences used for RT-PCR for HBDs -1, 2 and 3
Gene Primer type Sequence (50 ﬁ 30)
hBD-1 Sense TTg TCT gAg ATg
Antisense ATA CTT CAA AA
hBD-2 Sense CCA gCC ATC Ag
Antisense CAT gTC gCA CgT
hBD-3 Sense AgC CTA gCA gC
Antisense CTT Cgg CAg CATseparated on a 2% agarose gel. A molecular DNA (1 kbp) size
marker was also run to match the position of the base-pairs of
the positive PCR bands. Distilled water was included in the
reaction as a negative control.
2.5. Statistical analysis
All data were collected and analyzed with SPSS statistical soft-
ware (SPSS for Windows, release 15.0, version 20; SPSS, Inc.,
Chicago, IL). The mean values of the clinical parameters (GI,
PLI, PD, and CLA) were computed and evaluated before and
after periodontal therapy with a paired Student’s t-test. The
frequency (i.e., percentage of samples found to be positive
for a particular defensin) of the mRNA expression of HBD-
1, -2, and -3 in patients and healthy subjects was evaluated
by the Chi-square test. Differences between healthy control
subjects and diseased patients regarding the frequency of
expression of HBD-1, -2, and -3 as well as differences from
baseline to 3 months after periodontal therapy were evaluated
by McNemar’s test. Pearson’s correlation analysis was used to
study the correlation between the clinical parameters and the
frequency of expression of HBD-1, -2, and -3 at baseline and
after periodontal therapy. A P-value of less than 0.05 was con-
sidered signiﬁcant.
3. Results
Table 2 shows the changes in the scores and measurements of
PLI, GI, PD and CLA from baseline to 3 months after peri-
odontal therapy in the localized aggressive periodontitis pa-
tients. Signiﬁcant differences in the patient group from
baseline to 3 months after periodontal therapy were found
for all measures examined (Fig. 1).
PCR analysis was performed for GCF samples collected
from patients at baseline and 3 months after periodontal ther-
apy as well as PCR assay for GCF samples from the healthy
control subjects for detection of mRNA transcripts of HBDs
-1, 2 and 3. Table 3 shows the detection frequency of human
b defensins – 1, 2 and 3 mRNA transcripts in patients and
healthy control subjects. In the patient group at baseline; the
detection frequency for mRNA transcripts of the three defen-
sins was 30%, 85% and 35% respectively but the detection fre-
quency had changed after periodontal therapy to be 80%, 45%
and 85% for HBD – 1, 2 and 3, respectively. There was a sta-
tistically very high signiﬁcant difference in the detection fre-
quency of mRNA of HBD-1, 2, and 3 from baseline to
3 months after periodontal therapy (P< 0.001), Figs. 2–5.
The detection frequency of HBDs in the healthy control
subjects was 95%, 40% and 95% for HBD -1, 2 and 3, respec-
tively. On comparing the detection frequency of the mRNA
transcripts for the three defensins in the patient group at(Invitrogen, Paisley, United Kingdom).
PCR product size (bp)
gCC TCA ggT AAC 253
gCAA TTT TCC TTT AT
C CAT gAg ggT CTT g 295
CTC TgA TgA ggg Agg
T ATg Agg ATC 205
TTT Cgg CCA
Table 2 Mean scores and measurements of clinical parameters at baseline and after periodontal therapy in the patient group and in
the control group.
Before therapy X ± SD After therapy X ± SD Mean diﬀerence X ± SD t Value P value
Patients
GI 1.94 ± 0.33 0.73 ± 0.18 1.21 ± 0.23 11.94 <0.01
Pl-I 2.14 ± 0.57 0.84 ± 0.34 1.30 ± 0.23 7.53 <0.01
PD 5.12 ± 0.23 3.74 ± 0.63 1.38 ± 0.40 4.66 <0.05
CLA 5.76 ± 0.53 4.35 ± 0.73 1.41 ± 0.34 5.12 <0.05
Healthy control group
Age mean ± SD GI mean ± SD Pl-I mean ± SD Crevice depth mean ± SD CLA
24.38 ± 6.54 0.61 ± 0.23 0.45 ± 0.23 2.43 ± 0.55 0.0
0 
1 
2 
3 
4 
5 
6 
7 
GI PLI PD CLA 
Clinical periodontal parameters
mean difference
after therapy
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Figure 1 Mean scores and measurements of clinical periodontal parameters at baseline and 3 months after periodontal therapy together
with the mean difference in the studied patient group.
Table 3 Detection frequency of mRNA of the HBDs – 1, 2 and 3 in healthy subjects and differences of HBDs mRNA expression
frequencies in the studied patient group at baseline and 3 months after periodontal therapy.
Defensin RT-PCR expression levels
Before therapy After therapy P value
Frequency No. 20 Frequency No. 20
LAP Patients
HBD-1 30% 6 80% 16 <0.001
HBD-2 85% 17 45% 9 <0.01
HBD-3 35% 7 80% 16 <0.001
Diﬀerences between patients and control subjects Diseased patients No. 20 Healthy subjects No. 20 P value
HBD-1 30% 6 95% 19 <0.001
HBD-2 85% 17 40% 8 <0.01
HBD-3 35% 7 95% 19 <0.001
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statistically signiﬁcant difference (P< 0.001) in HBD-1 and
HBD-3 detection frequency, and there was a highly signiﬁcant
difference in HBD-2 detection frequency, Fig. 2.
Table 4 shows the correlations between the clinical peri-
odontal parameters and the detection frequency of the mRNA
transcripts for the human b defensins -1, 2 and 3; in the patient
group at baseline and 3 months after periodontal therapy, atbaseline there was a signiﬁcant positive correlation between
all periodontal parameters and the detection frequency of
HDB-2 mRNA with the correlation coefﬁcient (r) ranging
from 0.470 to 0.655. There was a signiﬁcant inverse positive
correlation between all clinical periodontal parameters and
the detection frequency of HBD-1mRNA and HBD-3mRNA
with (r) ranging from 0.487 to 0.765. Three months after peri-
odontal therapy the same correlations were reported for the
0% 
10% 
20%
30% 
40% 
50% 
60% 
70%
80% 
90%
100% 
baseline after therapy healthy 
HBD-1 
HBD-2 
HBD-3 
Figure 2 Detection frequencies of HBDs – 1, 2 and 3 mRNA transcripts in healthy subjects and in the patient group at baseline and
3 months after periodontal therapy.
Figure 3 RT-PCR assay result for detection frequency of
mRNA transcripts of HBD-1, lanes 1 and 3 represent baseline
positive assay result, lanes 2 and 4 represent positive assay results
obtained 3 months after periodontal therapy, M lane represents
the DNA size marker.
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to 0.870 for HBD-1, Fig. 6.Figure 4 RT-PCR assay result for detection frequency of mRNA tran
assay result, lanes 2 and 3 represent positive assay results obtained 3 m
result for healthy control subjects, M lane represents the DNA size m4. Discussion
The expression of HBDs has been widely observed in epithelial
tissues, saliva, and GCF (Vianna et al., 2009; Garcia et al.,
2001a,b; Diamond et al., 2001; Darveau et al., 2000).
This study was conducted on a group of patients suffering
from localized aggressive periodontitis. All patients were sub-
jected to clinical periodontal examination and nonsurgical
periodontal therapy combined with 100 mg doxycycline twice
daily as both an antibiotic and to block the collagenase activity
and modulate the immune host response.
Recent studies have shown that HBDs play major roles in
the chemotactic immune and inﬂammatory responses of imma-
ture dendritic cells, memory T-cells, and monocytes. The
expression patterns of HBD-1, -2, and -3 provide evidence of
the antimicrobial barriers of gingival epithelia (Bensch et al.,
1995; Nomura et al., 2003), which is consistent with the results
of the present study regarding the expression frequencies of
HBD-1 and HBD-3. In particular, the expression frequencies
of the two defensins increased after periodontal therapy. This
observation may indicate that the expression of these defensins
is required for antimicrobial functions but is reduced by
inﬂammation. By using periodontal therapy and decreasing
the bacterial challenge, the frequency of expression of these
two defensins may be increased.scripts of HBD – 2, lanes 1, 5, 6, 8 and 9 represent baseline positive
onths after periodontal therapy, lanes 7 and 4 are positive assay
arker.
Figure 5 RT-PCR assay result for detection frequency of mRNA transcripts of HBD – 3, lanes 1 and 2 represent the positive baseline
assay results, lanes 3 and 4 are the positive assay results obtained 3 months after periodontal therapy, lanes 5 and 6 represent positive assay
result for two healthy control subjects, M lane represents the DNA size marker.
Table 4 Correlation between the expression patterns of mRNA of defensins -1, 2 and 3 by RT-PCR and the clinical periodontal
parameters in the studied patient group at baseline and 3 months after periodontal therapy.
Frequency of expression GI X ± SD 1.94 ± 0.33 Pl-I X ± SD 2.14 ± 0.57 PD X± SD 5.12 ± 0.23 CLA X± SD 5.76 ± 0.53
Baseline
HBD-1 0.650 0.543 0.565 0.487
P value <0.01 <0.05 <0.05 <.0.05
HBD-2 0.655 0.470 0.580 0.547
P value <0.01 <0.05 <0.01 <0.05
HBD-3 0.560 0.576 0.564 0.765
P value <0.05 <0.05 <0.05 <0.001
Frequency of expression GI X ± SD 0.73 ± 0.18 Pl-I X ± SD 0.84 ± 0.23 PD X± SD 3.74 ± 0.63 CLA X± SD 4.35 ± 0.73
After therapy
HBD-1 0.576 0.870 0.570 0.675
P value <0.05 <0.001 <0.05 <0.01
HBD-2 0.565 0.490 0.654 0.554
P value <0.05 <0.05 <0.01 <0.05
HBD-3 0.564 0.525 0.480 0.465
P value <0.05 <0.05 <0.05 <0.05
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Figure 6 Correlation between the expression patterns of mRNA of defensins – 1, 2 and 3 by RT-PCR and the clinical periodontal
parameters in the studied patient group at baseline and after periodontal therapy.
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regulated by several inﬂammatory mediators that are mainly
associated with inﬂammation. Proinﬂammatory cytokines, such
as IFN-c, IL-1b, IL-6, andTNF-a, have been shown tohave var-
ied effects on the expression of the HBDs. For example, IFN-c,
IL-1b, and IL-6 upregulate HBD-3 expression, but IL-1b only
induces upregulation of HBD-2 expression (Pingel et al., 2008;
Romani and Schuler, 1992). Based on the assumption that
aggressive periodontitis is an inﬂammatory disease that is asso-
ciatedwith the release of catabolic cytokines such as IL-1B, IL-8,
and TNF-a, this differential regulation of HBDs may support
the view that HBD-1, -2, and -3 are expressed in diseased gingi-
val tissue as antibacterial agents. This possibility is consistent
with the results of the current study regarding HBD-2. We
showed the increased frequency of expression of HBD-2 in
GCF from tissues affected by localized aggressive periodontitis,
which decreased after periodontal therapy to a frequency similar
to that of healthy subjects. Our results are inconsistent with
those of Zhao et al. (1996), who found a decreased expression
of HBD-2 in inﬂamed tissues.
The subgingival microﬂora vary dramatically between
healthy and periodontitis sites (Jin et al., 1999; Dale et al.,
2001), suggesting that periodontitis is a multifactorial inﬂam-
matory disease with a complex pathogenesis. This observation
also indicates that there is a difference in HBD expression be-
tween healthy and diseased sites. The complex expression of
HBDs may explain the diverse results obtained in this study
because different defensin expression frequencies were found
for healthy subjects and aggressive periodontitis patients, as
well as for patients before and after periodontal therapy Lu
et al., 2005.
In addition, Aas et al. (2005) reported a similar expression
pattern for HBD-1 and -2 in healthy and diseased gingival tis-
sues that was in agreement with the present study. Based upon
the differences in the HBD expressions in the GCF samples
collected from healthy and inﬂamed tissues, it can be suggested
that in a healthy oral cavity the levels of HBD-1 and -3 pep-
tides expressed in basal cells are sufﬁcient for protection and
to maintain host homeostasis. However, in the clinically un-
healthy state, more peptide will be expressed in the suprabasal
epithelial layers to resist the invading pathogens. Finally, dur-
ing tissue destruction, the deeply located HBD-1 and -3 pep-
tides will not be sufﬁcient to resist the pathogens, leading to
increased peptide expression in the spinous layers––accompa-
nied by expression of HBD-2––to reinforce the antimicrobial
activity of defensins against the invading pathogens. Accord-
ingly, this study provides clear evidence that the expression fre-
quencies of the HBDs are associated with periodontal health
and disease.
The limitation of this study was the inability to study the
actual levels of defensins before and after periodontal therapy.5. Conclusions
This study shows that HBD mRNA transcripts are frequently
expressed in the GCF in both healthy and unhealthy subjects.
The appropriate expression of HBD peptides may contribute
to the maintenance of periodontal homeostasis, possibly
through their antimicrobial effects and the promotion of adap-
tive immune responses.6. Recommendations
Further investigation using real-time PCR is warranted to
determine the exact changes in the levels of the HBD peptides
in response to surgical and nonsurgical periodontal therapy
and to determine the exact role of these antimicrobial peptides
in the maintenance of periodontal homeostasis.Conﬂicts of interest
The author of the study conﬁrms that there are no any known
conﬂicts of interest associated with this publication.
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